Last update June 30, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
(-)-N-Methyl-γ-(2-methylphenoxy)-benzenepropanamine hydrochloride is Atomoxetine Hydrochloride in Chemical name.
Is written in other languages:(-)-N-Methyl-γ-(2-methylphenoxy)-benzenepropanamine hydrochloride is also known as
(-)-N-Methyl-γ-(2-methylphenoxy)-benzenepropanamine hydrochloride belongs to this group or family:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 63 - 94 | % |
Molecular weight | 292 | daltons |
Protein Binding | 98 | % |
VD | 0.85 | l/Kg |
Tmax | 1 - 2 | hours |
T½ | 3.6 - 21 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a selective norepinephrine reuptake inhibitor used in the treatment of attention deficit hyperactivity disorder (ADHD). Oral administration once or twice daily.
On latest update relevant data on breastfeeding was not found.
Its high plasma protein binding and very wide volume of distribution make it highly unlikely that significant quantities will pass into breast milk.
No problems were seen in two infants whose mothers were taking it. (Besag 2014)
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.